Bayer appoints Tara Frenkl as new head of oncology development at oncology strategic business unit

"We are pleased to welcome Tara as the new Head of Oncology Development. Her broad experience, passion and dedication go hand in hand with Bayer`s commitment to put patients at the center of it all. It is important that we stay focused on the science coupled with speed and innovation to help bring new medications and indications as quickly as possible," said Christine Roth. "Tara`s leadership style is characterized by expertise and innovative thinking. She brings experience from all aspects of research and development, including clinical development, regulatory and global development strategy."

Prior to joining GlaxoSmithKline, Tara Frenkl was at Merck & Co., Inc. for 13 years in roles of increasing responsibility.